Published in J Immunol on January 01, 2001
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood (2010) 2.52
Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother (2009) 2.35
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
In vitro membrane reconstitution of the T-cell receptor proximal signaling network. Nat Struct Mol Biol (2014) 1.12
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Hematopoietic stem cells for cancer immunotherapy. Immunol Rev (2014) 0.95
Systems model of T cell receptor proximal signaling reveals emergent ultrasensitivity. PLoS Comput Biol (2013) 0.94
T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med (2005) 0.93
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation. J Immunol (2010) 0.89
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res (2013) 0.89
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
Advancement and prospects of tumor gene therapy. Chin J Cancer (2011) 0.85
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
T lymphocytes isolated from patients with advanced colorectal cancer are suitable for gene immunotherapy approaches. Br J Cancer (2003) 0.80
An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget (2014) 0.77
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Redirecting mouse T hybridoma against human breast and ovarian carcinomas: in vivo activity against HER-2/neu expressing cancer cells. Br J Cancer (2003) 0.76
Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice. PLoS One (2015) 0.76
Engineering Chimeric Antigen Receptors. Acta Naturae (2017) 0.75
The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol Immunother (2017) 0.75
Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med (2000) 4.45
NKT cells: facts, functions and fallacies. Immunol Today (2000) 4.40
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD-like domains. Proc Natl Acad Sci U S A (1996) 3.53
Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 3.04
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med (2001) 2.74
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Extracellular adenosine triphosphate and adenosine in cancer. Oncogene (2010) 2.53
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia (2009) 2.50
Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood (2001) 2.45
Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene (1997) 2.35
Enforced expression of the GATA-2 transcription factor blocks normal hematopoiesis. Blood (1999) 2.14
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A (2007) 2.10
The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator CPP32. J Biol Chem (1996) 2.07
Purification of the human NF-E2 complex: cDNA cloning of the hematopoietic cell-specific subunit and evidence for an associated partner. Mol Cell Biol (1993) 2.05
NKT cells are phenotypically and functionally diverse. Eur J Immunol (1999) 1.97
Initiation of apoptosis by granzyme B requires direct cleavage of bid, but not direct granzyme B-mediated caspase activation. J Exp Med (2000) 1.89
The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge. Oncogene (2006) 1.88
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis. J Biol Chem (1997) 1.88
Perforin is a major contributor to NK cell control of tumor metastasis. J Immunol (1999) 1.83
Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today (1995) 1.76
A cytosolic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem (1996) 1.75
Role of ceramide in cellular senescence. J Biol Chem (1995) 1.74
P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood (1999) 1.61
Perforin and serine esterase gene expression in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A. J Exp Med (1989) 1.60
Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol (1998) 1.59
Multiple physiological functions for multidrug transporter P-glycoprotein? Trends Biochem Sci (2000) 1.58
Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci U S A (1992) 1.55
Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization. J Exp Med (1997) 1.54
NKT cells and tumor immunity--a double-edged sword. Nat Immunol (2000) 1.53
Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med (1999) 1.45
CD1-restricted T cells and tumor immunity. Curr Top Microbiol Immunol (2007) 1.45
A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ (2003) 1.44
Targeting death-inducing receptors in cancer therapy. Oncogene (2007) 1.42
Cytometric and functional analyses of NK and NKT cell deficiencies in NOD mice. Int Immunol (2001) 1.40
Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin. Mol Cell Biol (1999) 1.39
Efficient nuclear targeting of granzyme B and the nuclear consequences of apoptosis induced by granzyme B and perforin are caspase-dependent, but cell death is caspase-independent. J Biol Chem (1998) 1.36
Erythroid Kruppel-like factor (EKLF) coordinates erythroid cell proliferation and hemoglobinization in cell lines derived from EKLF null mice. Blood (2001) 1.34
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31
Bcl-2 prevents apoptosis induced by perforin and granzyme B, but not that mediated by whole cytotoxic lymphocytes. J Immunol (1997) 1.25
Unlocking the secrets of cytotoxic granule proteins. J Leukoc Biol (2001) 1.25
Constitutive expression of pore-forming protein in peripheral blood gamma/delta T cells: implication for their cytotoxic role in vivo. J Exp Med (1990) 1.24
Induction of human fetal globin gene expression by a novel erythroid factor, NF-E4. Mol Cell Biol (2000) 1.24
A new family of 10 murine ovalbumin serpins includes two homologs of proteinase inhibitor 8 and two homologs of the granzyme B inhibitor (proteinase inhibitor 9). J Biol Chem (1997) 1.23
Processing of the Nedd2 precursor by ICE-like proteases and granzyme B. Genes Cells (1996) 1.23
Transcription and growth regulatory functions of the HIN-200 family of proteins. Mol Cell Biol (1999) 1.20
Partial agonists and antagonists reveal a second permeability state of human lymphocyte P2Z/P2X7 channel. Am J Physiol (1998) 1.19
Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth. Cell Immunol (2001) 1.19
The human cytotoxic T cell granule serine protease granzyme H has chymotrypsin-like (chymase) activity and is taken up into cytoplasmic vesicles reminiscent of granzyme B-containing endosomes. J Biol Chem (1999) 1.18
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology (1985) 1.18
Localization of granzyme B in the nucleus. A putative role in the mechanism of cytotoxic lymphocyte-mediated apoptosis. J Biol Chem (1996) 1.17
Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro. J Biol Chem (1996) 1.16
Immunopurification of functional Asp-ase (natural killer cell granzyme B) using a monoclonal antibody. Biochem Biophys Res Commun (1993) 1.14
The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology. J Virol (1998) 1.13
The activation domain of the enhancer binding protein p45NF-E2 interacts with TAFII130 and mediates long-range activation of the alpha- and beta-globin gene loci in an erythroid cell line. Proc Natl Acad Sci U S A (1997) 1.12
Functional interaction between p53 and the interferon-inducible nucleoprotein IFI 16. Oncogene (2000) 1.12
Molecular mechanisms of natural killer cell activation in response to cellular stress. Cell Death Differ (2013) 1.11
p53-dependent ceramide response to genotoxic stress. J Clin Invest (1998) 1.11
Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway. J Immunol (2000) 1.10
The human interferon-inducible protein, IFI 16, is a repressor of transcription. J Biol Chem (1998) 1.10
Exploration of the Common Bile Duct for Stone. Drainage with T-Tube and Cholangiography. Br Med J (1941) 1.07
CTL granules: evolution of vesicles essential for combating virus infections. Immunol Today (1999) 1.07
Evolution in action. Nature (1974) 1.06
Description of a mouse monoclonal anti-HLA-B27 antibody HLA-ABC-m3. Hum Immunol (1983) 1.06
Granzymes: a variety of serine protease specificities encoded by genetically distinct subfamilies. J Leukoc Biol (1996) 1.05
Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids. Oncogene (2006) 1.05
The role of perforin and granzymes in diabetes. Cell Death Differ (2009) 1.04
Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. J Cell Physiol (1996) 1.04
NK cells and apoptosis. Immunol Cell Biol (1999) 1.04
Perforin deficiency and susceptibility to cancer. Cell Death Differ (2010) 1.02
Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Curr Opin Immunol (2000) 1.02
Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens (2009) 1.01
Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen. Gene Ther (2010) 1.00
The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br J Pharmacol (1994) 1.00
HMBA induces activation of a caspase-independent cell death pathway to overcome P-glycoprotein-mediated multidrug resistance. Blood (2000) 1.00
Aberrant sphingolipid signaling is involved in the resistance of prostate cancer cell lines to chemotherapy. Cancer Res (1999) 0.99
A role for P-glycoprotein in regulating cell death. Leuk Lymphoma (2000) 0.99
The structure and function of mammalian membrane-attack complex/perforin-like proteins. Tissue Antigens (2010) 0.98
Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health (2006) 0.98
The interferon-inducible autoantigen, IFI 16: localization to the nucleolus and identification of a DNA-binding domain. Biochem Biophys Res Commun (1995) 0.98
P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ (2002) 0.97
Functional dissociation of DeltaPsim and cytochrome c release defines the contribution of mitochondria upstream of caspase activation during granzyme B-induced apoptosis. Cell Death Differ (2006) 0.97
Perforin-independent expression of granzyme B and proteinase inhibitor 9 in human testis and placenta suggests a role for granzyme B-mediated proteolysis in reproduction. Mol Hum Reprod (2001) 0.97
Controversies in granzyme biology. Tissue Antigens (2012) 0.97
Targeted disruption of the CP2 gene, a member of the NTF family of transcription factors. J Biol Chem (2000) 0.96
Isotypic variants of the interferon-inducible transcriptional repressor IFI 16 arise through differential mRNA splicing. Biochemistry (1998) 0.96
Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ (2004) 0.96
Granule serine proteases are normal nuclear constituents of natural killer cells. J Biol Chem (1994) 0.95
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. Cell Death Differ (2013) 0.95
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol (2000) 0.94